Compounded Semaglutide and Tirzepatide: Are They Safe and Legal in 2026? | Philadelphia

TL;DR30-second take

Compounded semaglutide and tirzepatide are versions mixed by compounding pharmacies rather than made by the brand manufacturers. They became widely available during the 2022 to 2024 shortages, when compounding was allowed to fill the gap. Those shortages are now over, tirzepatide since late 2024 and semaglutide since February 2025, and the deadlines to stop large-scale compounding passed in the spring of 2025, so mass-market compounded GLP-1 is no longer the legitimate mainstream route it once was. In 2026 the FDA proposed to keep these drugs off the list that would allow large-batch compounding, though that is still a proposal. The core difference to understand is that the brand drugs are reviewed by the FDA for safety, quality, and effectiveness, while compounded versions are not reviewed before use. Compounding is still legal for a documented medical need the approved drug cannot meet, but not for price or convenience alone.

TL;DR: Compounded semaglutide and tirzepatide are versions mixed by compounding pharmacies rather than made by Novo Nordisk or Eli Lilly. They flooded the market during the 2022 to 2024 shortages, when the law lets compounders fill a gap. Those shortages have since been declared over, tirzepatide in late 2024 and semaglutide in February 2025, and the deadlines for compounders to stop making copies passed in the spring of 2025. In 2026 the FDA went further and proposed to keep these drugs off the list that would permit large-batch compounding, though that step is still only a proposal. So the sweeping, cheap, telehealth-compounded GLP-1 of a couple of years ago is no longer the legitimate mainstream path. The honest core of the issue is that the brand drugs are tested by the FDA for safety, quality, and effectiveness, while compounded versions are not reviewed before you use them. Documented problems have shown up, including dosing overdoses, non-standard forms of the drug, foreign-sourced ingredients, and specific sterility recalls, though none of these is universal. Compounding still has a narrow, legitimate place for a documented medical need, and with the manufacturers now offering self-pay prices around 300 to 500 dollars a month, the old price argument has shrunk.

What is compounded semaglutide or tirzepatide?

Compounding is the practice of a pharmacy mixing or preparing a medication itself, rather than dispensing a finished product from a manufacturer. It is a legitimate and long-standing part of medicine, meant to serve needs the mass-produced drug cannot, such as a liquid version for someone who cannot swallow pills, or a formula that leaves out a dye a patient is allergic to.

Compounded semaglutide and tirzepatide are versions of those GLP-1 drugs prepared by compounding pharmacies instead of by Novo Nordisk, which makes semaglutide as Ozempic and Wegovy, or Eli Lilly, which makes tirzepatide as Mounjaro and Zepbound. They became widespread because the law allows compounders to step in when an approved drug is in short supply, and from 2022 through 2024 these drugs were in heavy shortage.

The single most important thing to understand sits underneath all of this. The brand-name drugs are approved by the FDA, which means the agency has reviewed them for safety, effectiveness, and manufacturing quality before they reach you. Compounded versions are not FDA-approved and are not reviewed by the agency for any of those things before use. That difference in oversight is the heart of the safety conversation.

Is compounded GLP-1 still legal in 2026?

The legal ground shifted, and the timeline matters, so here it is plainly.

During a shortage, compounders may make a version of a drug that is otherwise a copy of the brand. That permission ends when the shortage ends. The FDA declared the tirzepatide shortage resolved in late 2024 and the semaglutide shortage resolved in February 2025. It then set deadlines for compounders to wind down: the traditional pharmacies had until roughly February and April of 2025, and the larger outsourcing facilities until roughly March and May of 2025.¹ Courts declined to pause those deadlines, so they held. After they passed, making compounded copies of these drugs at scale was no longer permitted.

In 2026 the FDA moved to close the remaining large-scale route. On April 30, 2026, it proposed to keep semaglutide, tirzepatide, and liraglutide off the list that would let outsourcing facilities compound them in bulk even without a shortage.² That proposal went through public comment in mid-2026 and, as of now, is not yet a final rule, so it is a direction rather than settled law. Still, the message is consistent: the era of broad, cheap, mass-market compounded GLP-1 is closing.

What remains legal is narrower. A pharmacy may still compound a version for a specific patient with a documented medical need that the approved product cannot meet, such as a true allergy to an inactive ingredient, or a strength or form that is not sold commercially. What is not a valid reason, by the FDA's own standard, is that the compounded version is cheaper or more convenient. That distinction, a documented clinical difference for you versus a way to save money, is the line regulators draw.

What are the safety concerns?

The concerns are documented and worth taking seriously, and they are also worth keeping in proportion. These are recorded problems and recalls, rather than a measured rate that applies to every compounded dose. Here are the four that matter most.

The first is dosing errors. Many compounded products come in a vial, and the patient draws up each dose with a syringe, rather than using a pre-set pen. That has led to mistakes, with people confusing units, milliliters, and milligrams and taking five to ten times the intended dose, and in some reports even more. The FDA issued a safety alert about this in 2024, and calls to poison control centers about semaglutide rose sharply that year, roughly 69% in the first half compared with the year before.³ Those poison-center figures cover all semaglutide, brand and compounded together, so they should not be pinned on compounding alone, but the self-draw vial is a clear source of the overdoses.

The second is the form of the active ingredient. Some compounders used salt forms of semaglutide, such as semaglutide sodium or semaglutide acetate, which the FDA has stated are different active ingredients from the semaglutide in the approved drugs, are not shown to be safe and effective, and have no lawful basis for use in compounding.⁴ A product built on one of these is not the same medicine as the brand, even if the label looks similar.

The third is sourcing. Independent analyses, including reports to Congress, found that a large amount of the raw drug used in compounded GLP-1 was imported from overseas facilities not registered with or inspected by the FDA, much of it from China. Because the FDA does not review compounded products before use, there is no agency check on the identity, purity, or strength of what ends up in the vial.

The fourth is sterility. These are injectable drugs, so they must be made sterile. There have been specific recalls of compounded GLP-1 products for failing to assure sterility, and the FDA has sent warning letters to sterile compounders during its enforcement push. These were particular facilities that fell short, rather than proof that all compounded product is contaminated, but they show the quality risk is not hypothetical.

Does the type of pharmacy matter? 503A versus 503B

If you are looking at a compounded product, one distinction is useful to know, because the two kinds of compounders operate under different rules.

A 503A pharmacy is a traditional compounding pharmacy, licensed by its state board and preparing medications for a specific patient with a prescription. These pharmacies are not required to register with the FDA and are not held to the federal manufacturing-quality standards that brand makers follow, though they do work under state rules and pharmacy standards.

A 503B pharmacy is called an outsourcing facility. It can make larger batches, it registers with the FDA, and it is required to follow the more rigorous federal manufacturing-quality standards, including batch testing. So a 503B operates under closer oversight than a 503A, and far closer than an unregistered or offshore seller. None of this makes a compounded drug equal to the FDA-approved product, but a vial of unclear origin bought from a website is a different risk level than a product from a registered facility.

What about the price difference?

Price was the engine of the whole compounded boom, so it deserves an honest look.

At the peak, compounded semaglutide or tirzepatide ran roughly 150 to 300 dollars a month, against brand list prices around 1,000 to 1,350 dollars, a gap wide enough to send many people to telehealth sellers. That gap is what made the convenience and the risk feel worth it.

The picture in 2026 is different, because the manufacturers responded. Both now sell directly to patients paying without insurance, at prices far below the old list figures. Eli Lilly's self-pay vials of tirzepatide and Novo Nordisk's direct pharmacy program for semaglutide brought monthly costs into roughly the 300 to 500 dollar range. That is still meaningful money, and more than the cheapest compounded offers, but it narrows the gap enough that the price argument for taking on the compounded risks is weaker than it was. For many people, an FDA-approved product through insurance or one of these self-pay routes is now within reach.

Guidance from the Clinic

"This is one where the ground moved under people's feet. A patient signed up for a cheap compounded version during the shortage, it worked, and now they are unsure whether it is still legitimate or safe. What I tell them is the plain version: the shortages are over, so the broad compounding that made those products legal has wound down, and the drug the FDA has tested is the brand one. I am not against compounding as a tool, it has a legitimate place for a specific medical need, but price alone is not that reason, and a vial you draw up yourself from a source you cannot verify carries risks the pen from the pharmacy does not. The part that has changed the conversation most is the price. With the manufacturers now selling self-pay in the few-hundred-dollar range, the reason most people reached for compounding has shrunk. My job is to find you the safest version you can afford and keep the dosing right."

Key Takeaways

Compounded semaglutide and tirzepatide are prepared by compounding pharmacies rather than the brand manufacturers, and are not FDA-approved or reviewed for safety, quality, or effectiveness before use.
The shortages that made broad compounding legal are over, tirzepatide since late 2024 and semaglutide since February 2025, and the deadlines to stop large-scale compounding passed in the spring of 2025.
In 2026 the FDA proposed to keep these drugs off the list that would allow large-batch compounding, a step that is still a proposal rather than a final rule.
Documented risks include dosing overdoses from self-draw vials, non-standard salt forms, foreign-sourced ingredients, and specific sterility recalls, though none of these is universal.
Compounding is still legal for a documented medical need the approved drug cannot meet, but not for price or convenience; with manufacturer self-pay now around 300 to 500 dollars a month, the price gap has narrowed.

Ozempic, Wegovy, and Mounjaro: The GLP-1 Strategy - how these drugs are prescribed and managed here
Tirzepatide (Zepbound, Mounjaro) - the approved dual agonist in depth
Medical Weight Loss and Body Composition - building a durable plan around the medication
Ozempic vs Metformin - choosing among metabolic drugs
GLP-1 Drugs and Surgery - another practical GLP-1 question, answered

Scientific References

US Food and Drug Administration. "FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize." 2025.
US Food and Drug Administration. "FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide from the 503B Bulks List." Press announcement, April 30, 2026.
US Food and Drug Administration. "FDA Alerts Health Care Providers, Compounders and Patients of Dosing Errors Associated with Compounded Injectable Semaglutide Products." July 26, 2024.
US Food and Drug Administration. "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss." 2024.

Fishtown Medicine | Metabolism

2418 E York St, Philadelphia, PA 19125(267) 360-7927 hello@fishtownmedicine.comHSA/FSA Eligible

Start your intake

Frequently Asked Questions

Common Questions

Only in a narrow way. The broad permission that existed during the shortage ended when the FDA declared the semaglutide shortage resolved in February 2025, and the deadlines for compounders to stop making copies passed in the spring of 2025. In 2026 the FDA proposed to keep the drug off the list that would allow large-batch compounding, though that is still a proposal. Compounding remains legal for a documented medical need the approved drug cannot meet, but not for price or convenience alone.

It is not tested the way the brand drug is. The FDA-approved products are reviewed for safety, quality, and effectiveness before use; compounded versions are not. Documented problems have included dosing overdoses from self-drawn vials, non-standard salt forms of the drug, ingredients sourced from uninspected foreign facilities, and specific recalls for sterility failures. None of these is universal, and compounding from a reputable pharmacy for a documented medical need is different from a vial of unknown origin bought online, but the oversight gap remains.

Because compounders were not paying to develop, test, and brand the drug, and because demand during the shortage created a large market. Compounded versions ran roughly 150 to 300 dollars a month against brand list prices near 1,000 to 1,350. That gap has narrowed in 2026, because the manufacturers now offer direct self-pay options in roughly the 300 to 500 dollar range, which brings an FDA-approved product within reach of more people.

The brand versions, Ozempic and Wegovy, are made by Novo Nordisk and approved by the FDA, which reviewed them for safety, effectiveness, and manufacturing quality. Compounded semaglutide is prepared by a compounding pharmacy and is not FDA-approved or reviewed before use. Depending on the compounder, it may also use a different form of the ingredient or a self-draw vial rather than a pen, which adds the dosing and quality questions the brand product does not carry.

It is harder and legally narrower than it was. The tirzepatide shortage was declared over in late 2024, and the deadlines to stop large-scale compounding passed in early 2025. Products are still findable online, but many now operate in legal gray zones or offshore, where you cannot verify the ingredient, the dose, or the sterility. A legitimate compounded version now generally requires a documented medical need the approved drug cannot meet, prepared by a licensed pharmacy.

Deep-Dive Questions

Because the law treats compounding during a shortage as a stopgap rather than a permanent alternative. Federal rules generally bar a compounder from making a product that is essentially a copy of an approved, commercially available drug, since that would undercut the tested product and its quality controls. A declared shortage creates a temporary exception, on the reasoning that access matters when patients cannot get the approved drug. Once the FDA declares the shortage resolved, the approved drug is deemed available again, the exception falls away, and making copies returns to being off-limits. That is why the resolution dates, late 2024 for tirzepatide and February 2025 for semaglutide, were the hinge, and why the FDA set wind-down deadlines rather than an instant cutoff.

Sometimes it does not have the same drug in it. Some compounded products used salt forms, semaglutide sodium or acetate, that the FDA considers different active ingredients from the semaglutide base in the approved drugs, with their own unproven safety and effectiveness. Even when the active ingredient is the same molecule, the finished product can differ in concentration, purity, and sterility, because it was mixed outside the tested, standardized manufacturing the brand uses, and often from raw material the FDA never inspected. And the delivery differs: a self-draw vial puts the measuring in the patient's hands, where a pen has the dose built in. So two products can share a name and still not be the same medicine in the ways that affect safety.

The honest answer is that many people used compounded GLP-1 without a known problem, so this is not a reason to panic, but it is a good reason to move toward a tested product now that the legal and price picture has changed. The specific risks, an overdose from mis-measuring a vial, a non-equivalent salt form, or a sterility failure at a particular facility, are documented but not universal, and they are hardest to judge because compounded products are not tracked and tested the way approved ones are. The sensible step is to talk with your physician about switching to an FDA-approved product through insurance or a manufacturer self-pay program, and in the meantime to be certain your dosing is right, since the self-draw vial is the most common source of harm.

A few things make the conversation productive. First, whether an FDA-approved product is affordable for you, through insurance or a manufacturer self-pay option, since that is the tested choice. Second, if a compounded version is seriously being considered, whether there is a documented medical reason the approved drug cannot meet, because that is the only footing on which compounding is now appropriate. Third, what kind of pharmacy would prepare it, a state-licensed 503A or an FDA-registered 503B outsourcing facility, rather than a seller of unclear origin. Fourth, how to measure and inject the dose if it comes as a vial. A good clinician will help you weigh the trade-off of a lower price against the loss of the FDA's quality review, rather than making the decision on cost alone.

Ready when you are